View older revisions Content changed at 2018-04-19, 1397/01/30

Protocol summary

Study aim
Effect of Ginger and Chamomile Mixed Sachet with Honey in The Treatment of Primary Dysmenorrhea and Associated Symptoms and Also Detection of Uterine Humor
Design
This study is a clinical trial and patients will divide randomly by block random sampling. 400 patients will divide to four groups by block random sampling, so that 100 people randomly will assign to each group.
Settings and conduct
During the menstrual cycle, patients of three groups will must dissolve the sachet in a glass of water and after heating, consume that with a teaspoonful of honey. For the mefenamic acid group, will provide 250 mg mefenamic acid capsules. Prescribing instruction is similar in all groups, patients will must start consuming sachets and capsules, 2 day before menstrual cycle and continue that to 3 day after the beginning of menstrual cycle, 3 time a day for 2 menstrual cycles. After the first and second cycle, the questionnaires will be filling to measure the amount of pain, bleeding severity, duration of bleeding and other symptoms of dysmenorrhea.
Participants/Inclusion and exclusion criteria
Inclusion criteria: Between 18 to 30 years old; Unmarried; Lack of chronic diseases; Without peptic ulcer or duodenal ulcer; Do not consume anticoagulant drugs; Do not consume oral contraceptives; Avoiding to use alcohol; Exclusion criteria: Patient's refusal to participate in the study; Consume drugs irregularly; Marriage; Do not fill out the questionnaire;
Intervention groups
For the ginger and chamomile mixed group, will provide sachets containing 1000 mg of ginger root powder and 5000 mg of chamomile, for the ginger group, will provide sachets that contain 1000 mg of ginger root powder and for the chamomile group, will provide sachets that contain 5000 mg of chamomile.
Main outcome variables
The severity of bleeding, Duration of bleeding, The severity of pain, Symptoms of dysmenorrhea

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT2016100825031N5
Registration date: 2016-11-08, 1395/08/18
Registration timing: registered_while_recruiting

Last update: 2018-04-19, 1397/01/30
Update count: 1
Registration date
2016-11-08, 1395/08/18
Registrant information
Name
Fatemeh Rafiei
Name of organization / entity
Arak University of Medical Science
Country
Iran (Islamic Republic of)
Phone
+98 86 3226 5732
Email address
a.rafiei@tafreshu.ac.ir
Recruitment status
Recruitment complete
Funding source
Arak University of Medical Sciences
Expected recruitment start date
2016-10-22, 1395/08/01
Expected recruitment end date
2017-10-21, 1396/07/29
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Comparison of the Efficacy of Ginger-Chamomile Mixed Sachet and Honey with Mefenamic Acid in The Treatment of Primary Dysmenorrhea and Associated Symptoms of Female Students that Living in the Arak University of Medical Sciences Dormitory: Randomized Controlled Clinical Trial
Public title
Effect of Ginger (Zingiber Officinale) and Chamomile Mixed Sachet with Honey in The Treatment of Primary Dysmenorrhea
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Between 18 to 30 years old Unmarried The menstruation pain is started before 20 years old Regular menstrual cycles between 21 to 35 days Menstrual bleeding without passing clots Menstrual pain start a few hours before menstrual bleeding and to continue for 5 days Lack of chronic diseases Without peptic ulcer or duodenal ulcer Do not consume anticoagulant drugs Lack of burning, itching and abnormal vaginal discharge Without history of allergy to medicinal plants Lack of stress in the past two months Do not have to take medicine or special diet and smoking Without history of pelvic inflammatory disease Without history of gynecologic surgery Do not transfer or relocation during the next 6 months Do not have pain in all the time of menstrual bleeding Do not consume oral contraceptives Do not consume drugs class of benzodiazepines, barbiturates, narcotics and some antidepressants, such as fluoxetine Avoiding to use alcohol, aspirin, warfarin and heparin Without having specific diseases of liver, kidney and diagnosed depression
Exclusion criteria:
Patient's refusal to participate in the study Consume drugs irregularly The incidence of significant stress factors during the study The incidence of any disease that requires to consume drugs, nutritional supplements or vitamins for long-term Doing any type of surgery during the study Marriage or change location Do not fill out the questionnaire Unwillingness to continue consume their medication by patients Avoiding the consume of medication as a single dose
Age
From 18 years old to 30 years old
Gender
Female
Phase
N/A
Groups that have been masked
  • Participant
  • Care provider
  • Investigator
  • Outcome assessor
  • Data analyser
  • Data and Safety Monitoring Board
Sample size
Target sample size: 280
Randomization (investigator's opinion)
Randomized
Randomization description
For Blindness and randomization will be used from numbered closed envelopes and block sampling
Blinding (investigator's opinion)
Double blinded
Blinding description
For Blindness will be used from numbered closed envelopes. Patients, researcher, physicians and statistical adviser do not know about the type of drug and groupings.
Placebo
Not used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics Committe of Arak University of Medical Sciences
Street address
Arak University of Medical Sciences, Basij Square, Sardasht, Arak, Iran
City
Arak
Province
Markazi
Postal code
3819693345
Approval date
2016-07-25, 1395/05/04
Ethics committee reference number
IR.ARAKMU.REC.1395.164

Health conditions studied

1

Description of health condition studied
Primary dysmenorrhoea
ICD-10 code
N94.4
ICD-10 code description
Primary dysmenorrhoea

Primary outcomes

1

Description
The severity of bleeding
Timepoint
Before intervention and after the first and third menstrual cycle
Method of measurement
(PBACs) Pictorial Blood Loss Assessment Chart

2

Description
Duration of bleeding
Timepoint
Before intervention and after the first and third menstrual cycle
Method of measurement
Measuring time

3

Description
The severity of pain
Timepoint
Before intervention and after the first and third menstrual cycle
Method of measurement
Visual analog scale

4

Description
Symptoms of dysmenorrhea
Timepoint
Before intervention and after the first and third menstrual cycle
Method of measurement
Verbal scale Anthresh - Mylsum

Secondary outcomes

empty

Intervention groups

1

Description
Group 1: sachet containing 1000 mg of ginger root powder and 5000 mg of chamomile with a teaspoonful of honey; 3 time a day, from 2 day before the beginning of menstrual cycle until 5 day
Category
Treatment - Drugs

2

Description
Group 2: sachet that contain 1000 mg of ginger root powder with a teaspoonful of honey; 3 time a day, from 2 day before the beginning of menstrual cycle until 5 day
Category
Treatment - Drugs

3

Description
Group 3: sachet that contain 5000 mg of chamomile with a teaspoonful of honey; 3 time a day, from 2 day before the beginning of menstrual cycle until 5 day
Category
Treatment - Drugs

4

Description
Group 4: 250 mg mefenamic acid capsule manufactured by Raha pharmaceutical company; 3 time a day, from 2 day before the beginning of menstrual cycle until 5 day
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Girl's Dormitory of Arak University of Medical Sciences
Full name of responsible person
Fatemeh Shabani
Street address
Girl's Dormitory of Arak University of Medical Sciences, Arak, Iran
City
Arak
Province
Markazi
Postal code
3819693345
Phone
+98 86 3417 3036
Email
info@arakmu.ac.ir

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Arak University of Medical Sciences
Full name of responsible person
Dr. Mohammad Rafiei
Street address
Amir-al-Momenin Hospital, Basij Square, Sardasht, Arak, Iran
City
Arak
Province
Markazi
Postal code
3819693345
Phone
+98 86 3417 3645
Email
info@arakmu.ac.ir
Grant name
-
Grant code / Reference number
-
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Arak University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Arak University of Medical Sciences
Full name of responsible person
Fatemeh Shabani
Position
M.Sc. in Midwifery
Latest degree
Master
Other areas of specialty/work
Midwifery
Street address
Nursing Faculty, Arak University of Medical Sciences, Arak, Iran
City
Arak
Province
Markazi
Postal code
3819693345
Phone
+98 86 3417 3524
Fax
Email
f.shabani@arakmu.ac.ir
Web page address

Person responsible for scientific inquiries

Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Dr. Fatemeh Nejatbakhsh
Position
Ph.D. in Traditional Medicine
Latest degree
Medical doctor
Other areas of specialty/work
Traditional Medicine
Street address
Traditional Medicine Faculty, Tehran University of Medical Sciences, Tehran, Iran
City
Tehran
Province
Tehran
Postal code
1417733161
Phone
+98 21 8899 0837
Fax
Email
nejatbakhsh@tums.ac.ir
Web page address

Person responsible for updating data

Contact
Name of organization / entity
Arak University of Medical Sciences
Full name of responsible person
Fatemeh Shabani
Position
M.Sc. in Midwifery
Latest degree
Master
Other areas of specialty/work
Midwifery
Street address
Nursing Faculty, Arak University of Medical Sciences, Arak, Iran
City
Arak
Province
Markazi
Postal code
3819693345
Phone
+98 86 3417 3524
Fax
Email
f.shabani@arakmu.ac.ir
Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available
Loading...